Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lung Cancer (Locally Advanced or Metastatic)”

657 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 657 results

Large-scale testing (Phase 3)Looking for participantsNCT06927986
What this trial is testing

Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

Who this might be right for
EGFR-mutated Locally Advanced or Metastatic NSCLC
CSPC Megalith Biopharmaceutical Co.,Ltd. 380
Not applicableStudy completedNCT02285361
What this trial is testing

GIOTRIF rPMS in Korean Patients With NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 1,272
Testing effectiveness (Phase 2)Looking for participantsNCT06616766
What this trial is testing

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)Solid Tumor
Yuhan Corporation 161
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Large-scale testing (Phase 3)Not Yet RecruitingNCT07416994
What this trial is testing

Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd. 440
Testing effectiveness (Phase 2)Study completedNCT00282022
What this trial is testing

VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Vion Pharmaceuticals 87
Large-scale testing (Phase 3)Looking for participantsNCT05382728
What this trial is testing

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

Who this might be right for
NSCLCEGFR Activating Mutation
TYK Medicines, Inc 680
Testing effectiveness (Phase 2)Ended earlyNCT05492045
What this trial is testing

Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer

Who this might be right for
NSCLC
InventisBio Co., Ltd 22
Early research (Phase 1)Study completedNCT01976741
What this trial is testing

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Who this might be right for
Neoplasms
Bayer 168
Testing effectiveness (Phase 2)Ended earlyNCT05662670
What this trial is testing

A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic NSCLC
Suzhou Junjing BioSciences Co., Ltd. 14
Early research (Phase 1)UnknownNCT04448379
What this trial is testing

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shanghai JMT-Bio Inc. 48
Post-approval studies (Phase 4)Study completedNCT01609543
What this trial is testing

Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 62
Not applicableStudy completedNCT03645330
What this trial is testing

Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL)

Who this might be right for
Non-small-Cell Lung Cancer
Chugai Pharmaceutical 1,026
Testing effectiveness (Phase 2)Ended earlyNCT05636267
What this trial is testing

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

Who this might be right for
NSCLC
Akeso 59
Large-scale testing (Phase 3)Ended earlyNCT03631199
What this trial is testing

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

Who this might be right for
Non-small Cell Lung Cancer
Novartis Pharmaceuticals 673
Large-scale testing (Phase 3)UnknownNCT00022009
What this trial is testing

Gemcitabine Plus Supportive Care in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
The Christie NHS Foundation Trust
Testing effectiveness (Phase 2)Ended earlyNCT04044170
What this trial is testing

Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Who this might be right for
NSCLC
Hanmi Pharmaceutical Company Limited 5
Early research (Phase 1)Active Not RecruitingNCT04042701
What this trial is testing

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Who this might be right for
Breast CancerNon-small Cell Lung Carcinoma
Daiichi Sankyo 115
Testing effectiveness (Phase 2)Active Not RecruitingNCT02864992
What this trial is testing

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Who this might be right for
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET AmplificationLung Adenocarcinoma Stage IIIB/IV
EMD Serono Research & Development Institute, Inc. 337
Large-scale testing (Phase 3)Active Not RecruitingNCT03787992
What this trial is testing

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc. 358
Load More Results